Show simple item record

AuthorRamli, Iman
AuthorCheriet, Thamere
AuthorPosadino, Anna Maria
AuthorGiordo, Roberta
AuthorZayed, Hatem
AuthorEid, Ali H.
AuthorPintus, Gianfranco
Available date2024-01-29T09:46:38Z
Publication Date2023-09-14
Publication NameFrontiers in Bioscience - Landmark
Identifierhttp://dx.doi.org/10.31083/j.fbl2809198
CitationRamli, I., Cheriet, T., Posadino, A. M., Giordo, R., Zayed, H., Eid, A. H., & Pintus, G. (2023). Potential therapeutic targets of resveratrol in the prevention and treatment of pulmonary fibrosis. Frontiers in Bioscience-Landmark, 28(9), 198.
ISSN2768-6701
URIhttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85174623807&origin=inward
URIhttp://hdl.handle.net/10576/51319
AbstractPulmonary fibrosis (PF) is a feared component in over 200 interstitial pulmonary diseases, which are characterized by increased alveolar wall thickness, excessive scarring, and aberrant extracellular matrix restructuring that, ultimately, affect lung compliance and capacity. As a result of its broad range of biological activities, including antioxidant, anti-inflammatory, antiapoptotic, and many others, resveratrol has been shown to be an effective treatment for respiratory system diseases, including interstitial lung disease, infectious diseases, and lung cancer. This work reviews the known molecular therapeutic targets of resveratrol and its potential mechanisms of action in attenuating PF in respiratory diseases, including cancer, COVID-19, interstitial lung diseases (ILDs) of known etiologies, idiopathic interstitial pneumonia, and ILDs associated with systemic disorders, such as rheumatoid arthritis, systemic sclerosis, Schrödinger’s syndrome, systemic lupus erythematosus, and pulmonary hypertension. The current issues and controversies related to the possible use of resveratrol as a pharmaceutical drug or supplement are also discussed.
SponsorThis work has been made possible thanks to grants from “Progetto Fondazione di Sardegna-Bando 2022–2023”, “FAR2020-Pintus”, and “DM 737/2021 resources 2021–2022, funded by the European Union - NextGenerationEU”.
Languageen
PublisherIMR Press Limited
Subjectinterstitial lung diseases
Nrf2
pulmonary fibrosis
resveratrol
SIRT1
TGF-ß1
TitlePotential Therapeutic Targets of Resveratrol in the Prevention and Treatment of Pulmonary Fibrosis
TypeArticle
Issue Number9
Volume Number28
ESSN2768-6698
dc.accessType Open Access


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record